Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Patent
1995-10-25
1998-12-29
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
4241581, 435 6, 435 791, 435 794, 435 912, 436 63, 436 87, 436811, 53038823, 5303892, A61K 39395, C07K 1624, C12P 2108, G10N 33543
Patent
active
058536973
ABSTRACT:
The present invention provides a method for treating the inflammatory response of an established colitis in a subject with inflammatory bowel disease (IBD), comprising administering to a subject diagnosed with an established colitis from an IBD an amount of an antibody to interleukin-12 effective in reducing the colitis-inducing effect of interleukin-12. Also provided is a method for screening a substance for its effectiveness in reducing the inflammatory response of an established colitis comprising obtaining an animal having an established colitis; administering the substance to an animal; and assaying the animal for an effect on interleukin-12 which results in the reduction of the inflammatory response of the colitis, an amount of reduction of the inflammatory response greater than the amount of reduction produced by the administration of antibodies against interferon-gamma or tumor necrosis factor-alpha indicating an effective substance. Additionally, the present invention provides a method for screening a substance for its effectiveness in preventing inflammatory bowel disease comprising administering the substance to an animal susceptible to colitis; subjecting the animal to a treatment that will induce a colitis; assaying the animal for the development of a colitis; and comparing the effectiveness of the substance in preventing development of a colitis to the effectiveness of antibodies to interferon-gamma or tumor necrosis factor-alpha in preventing development of a colitis, a substance more effective in preventing the development of a colitis than antibodies to interferon-gamma or tumor necrosis factor-alpha indicating an effective substance.
REFERENCES:
patent: 5547852 (1996-08-01), Kseiler et al.
Trembleau et al. The role of IL-12 in the induction of organ-specfic autoimmune disease Immunol. Today 16(8):383-386, 1995.
Powrie, F. et al. Therapeutic Immunol. 2 (2): 115-123, Apr. 1995.
Fretland, D. J. et al. J. Pharmacology and Experimental Therap. 225 (2): 572-576, Nov. 1990.
Leonard. J. P. et al. J. Exp. Med. 181 (1): 381-386, Jan. 1995.
Marcus, A. J. et al. J. Pharm. Pharmacol. 41 (6): 423-426, Jun. 1989.
Rask-Madsen, J. et al. Agents and Actions Spec. No. C37-46, 1992.
Sharon, P. et al. Gastroenterology 88 (1 Pt 1): 55-63, Jan. 1985.
Banic, M. et al. Alimentary Pharmacology and Therapeutics 7 (2): 201-206, Apr. 1993.
Schoenhaut, D. et al. J. Immunol. 148: 3433-3440, Jun. 1, 1992.
Brunda, M. J. Leukocyte Biol. 55: 280-288, Feb. 1994.
Harris, E. et al. TIBTECH 11:42-44, Feb. 1993.
Derkx, B. et al. Lancet 342: 173-174, Jul. 17, 1993.
Duchmann, R. et al. Immunol. Microbio. and Inflammatory Disorders Abstracts A693, Apr. 1993.
Strober, W. et al. Cell 75: 203-205, Oct. 22, 1993.
D'Andrea, A. et al. J. Exp. Med. 178: 1041-1048, Sep. 1993.
Wysocka et al. "Interleukin-12 is required for interferon-.gamma. production and lethality in . . . " Eur. J. Immounl. 25:672-676, 1995.
Van Dullemen et al. "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)" Gastroenterol. 109:129-135, Jul. 1995.
Leonard et al. "Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against Interleukin 12" Brief Definitive Report J. Exp. Med. 181:381-386, Jan. 1995.
Murray, Henry W. and Hariprashad, Jun. "Interleukin 12 is Effective Treatment for an Established Systemic Intracellular Infection: Experimental . . . " Brief Definitive Report J. Exp. Med. 181: 387-391, Jan. 1995.
Ling et al. "Human IL-12 p40 Homodimer Binds to the IL-12 Receptor but Does not Mediate Biologic Activity" J. of Immunol. 154:116-127, 1995.
Trinchieri, Giorgio "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells with Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 . . . " Blood 84(12):4008-4027, Dec. 15, 1994.
Powrie et al. "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in scid Mice Reconstituted with CD45RB.sup.hi CD4+ T Cells" Immunity 1:553-562, Oct 1994.
Kubin et al. "Interleukin 12 Synergizes with B7/CD28 Interaction in Inducing Efficient Proloferation . . . " J. Exp. Med. 180-:211-222, Jul. 1994.
Wynn et al. "Endogenous Interleukin 12 (IL-12) Regulates Granuloma Formation Induced by Eggs of Schistosoma mansoni and Exogenous IL-12 . . . " J. Exp. Med. 179:1551-1561, May 1994.
Powrie et al. "Regulatory Interactions between CD45RB.sup.high and CD45RB.sup.low CD4+ T Cells are Important for he Balance between . . . " J. Exp. Med. 179:589-600, Feb. 1994.
Seder et al. "Interleukin 12 Acts Directly on CD4+ T Cells to Enhance Priming for Interferon .gamma. Production and Diminishes Interleukin 4 Inhibition . . . " Proc.Natl. Acad. Sci Usa 90:10188-10192, Nov. 1993.
Strober, Warren and Ehrhardt, Rolf "Chronic Intestinal Inflammation: An Unexpected Outcome in Cytokine or T Cell Receptor Mutant Mice" Cell 75:205-205, Oct. 22, 1993.
Mombaerts et al. "Spontaneous Development of Inflammatory Bowel Disease in T Cell Receptor Mutant Mice" Cell 75:275-282, Oct. 22, 1993.
Duchmann et al. "Interleukin-12 mRNA is Induced in Lamina Propria Monoculear Cells from Patients with Inflammatory Bowel Disease (IBD)" Immumol., Microbiol. and Inflammatory Disorders Abstract A693. Apr. 1993.
Kuhn et al. "Interleukin-10-Deficient Mice Develop Chronic Enterocolotis" Cell 75:263-274, Oct. 22, 1993.
Sadlack et al. "Ulcerative Colitis-like Disease in Mice with a Disrupted Interleukin-1 Gene" Cell 75:253-261, Oct. 22, 1993.
Kulkarni et al. "Transforming Growth Factor .beta..sub.1 Null Mutation in Mice Causes Excessive Inflammatory Response and Early Death" Proc. Natl. Acad. Sci. USA 90:770-774, 1993.
Podlaski et al. "Molecular Characterization of Interleukin 12" Archives and Biochem. and Biophysics 294(1):230-237, Apr. 1992.
Morris et al. "Hapten-Induced Model of Chronic Inflammation and Ulceration in the Rat Colon" Gastroenterol. 96:795-803, 1989.
Fuss Ivan
Neurath Markus
Strober Warren
Eisenschenk Frank C.
Rabin Evelyn
The United States of America as represented by the Department o
LandOfFree
Methods of treating established colitis using antibodies against does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating established colitis using antibodies against, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating established colitis using antibodies against will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1421321